521 related articles for article (PubMed ID: 29473431)
21. Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas.
Lue JK; Prabhu SA; Liu Y; Gonzalez Y; Verma A; Mundi PS; Abshiru N; Camarillo JM; Mehta S; Chen EI; Qiao C; Nandakumar R; Cremers S; Kelleher NL; Elemento O; Amengual JE
Clin Cancer Res; 2019 Sep; 25(17):5271-5283. PubMed ID: 30979734
[TBL] [Abstract][Full Text] [Related]
22. Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program.
Kurmasheva RT; Sammons M; Favours E; Wu J; Kurmashev D; Cosmopoulos K; Keilhack H; Klaus CR; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27555605
[TBL] [Abstract][Full Text] [Related]
23. EZH2 inhibitors: a patent review (2014-2016).
Stazi G; Zwergel C; Mai A; Valente S
Expert Opin Ther Pat; 2017 Jul; 27(7):797-813. PubMed ID: 28394193
[TBL] [Abstract][Full Text] [Related]
24. Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020).
Dockerill M; Gregson C; O' Donovan DH
Expert Opin Ther Pat; 2021 Feb; 31(2):119-135. PubMed ID: 33103538
[TBL] [Abstract][Full Text] [Related]
25. The EZH2 inhibitor tazemetostat upregulates the expression of CCL17/TARC in B-cell lymphoma and enhances T-cell recruitment.
Yuan H; Nishikori M; Otsuka Y; Arima H; Kitawaki T; Takaori-Kondo A
Cancer Sci; 2021 Nov; 112(11):4604-4616. PubMed ID: 34449935
[TBL] [Abstract][Full Text] [Related]
26. Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas.
Bisserier M; Wajapeyee N
Blood; 2018 May; 131(19):2125-2137. PubMed ID: 29572378
[TBL] [Abstract][Full Text] [Related]
27. Acquired resistance to DZNep-mediated apoptosis is associated with copy number gains of AHCY in a B-cell lymphoma model.
Akpa CA; Kleo K; Oker E; Tomaszewski N; Messerschmidt C; López C; Wagener R; Oehl-Huber K; Dettmer K; Schoeler A; Lenze D; Oefner PJ; Beule D; Siebert R; Capper D; Dimitrova L; Hummel M
BMC Cancer; 2020 May; 20(1):427. PubMed ID: 32408898
[TBL] [Abstract][Full Text] [Related]
28. When to Use Targeted Therapy for the Treatment of Follicular Lymphoma.
Nastoupil LJ
Curr Hematol Malig Rep; 2021 Feb; 16(1):45-51. PubMed ID: 33797691
[TBL] [Abstract][Full Text] [Related]
29. EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications.
Li B; Chng WJ
J Hematol Oncol; 2019 Nov; 12(1):118. PubMed ID: 31752930
[TBL] [Abstract][Full Text] [Related]
30. Six Years (2012-2018) of Researches on Catalytic EZH2 Inhibitors: The Boom of the 2-Pyridone Compounds.
Fioravanti R; Stazi G; Zwergel C; Valente S; Mai A
Chem Rec; 2018 Dec; 18(12):1818-1832. PubMed ID: 30338896
[TBL] [Abstract][Full Text] [Related]
31. Refining the management of relapsed or refractory follicular lymphoma.
Pagel JM; Burke JM; Leslie LA
Clin Adv Hematol Oncol; 2020 Dec; 18 Suppl 20(12):1-24. PubMed ID: 33843893
[TBL] [Abstract][Full Text] [Related]
32. Carcinogenic roles and therapeutic effects of EZH2 in gynecological cancers.
Wan Z; Jiang H; Li L; Zhu S; Hou J; Yu Y
Bioorg Med Chem; 2020 Apr; 28(7):115379. PubMed ID: 32098708
[TBL] [Abstract][Full Text] [Related]
33. Naturally occurring anti-cancer agents targeting EZH2.
Shahabipour F; Caraglia M; Majeed M; Derosa G; Maffioli P; Sahebkar A
Cancer Lett; 2017 Aug; 400():325-335. PubMed ID: 28323035
[TBL] [Abstract][Full Text] [Related]
34. Tazemetostat: First Approval.
Hoy SM
Drugs; 2020 Apr; 80(5):513-521. PubMed ID: 32166598
[TBL] [Abstract][Full Text] [Related]
35. Targeting EZH2 as cancer therapy.
Hanaki S; Shimada M
J Biochem; 2021 Sep; 170(1):1-4. PubMed ID: 33479735
[TBL] [Abstract][Full Text] [Related]
36. Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors.
Gibaja V; Shen F; Harari J; Korn J; Ruddy D; Saenz-Vash V; Zhai H; Rejtar T; Paris CG; Yu Z; Lira M; King D; Qi W; Keen N; Hassan AQ; Chan HM
Oncogene; 2016 Feb; 35(5):558-66. PubMed ID: 25893294
[TBL] [Abstract][Full Text] [Related]
37. Targeting Enhancer of Zeste Homolog 2 for the Treatment of Hematological Malignancies and Solid Tumors: Candidate Structure-Activity Relationships Insights and Evolution Prospects.
Xia J; Li J; Tian L; Ren X; Liu C; Liang C
J Med Chem; 2022 May; 65(10):7016-7043. PubMed ID: 35531606
[TBL] [Abstract][Full Text] [Related]
38. EZH2: The roles in targeted therapy and mechanisms of resistance in breast cancer.
Chen Y; Zhu H; Luo Y; Tong S; Liu Y
Biomed Pharmacother; 2024 Jun; 175():116624. PubMed ID: 38670045
[TBL] [Abstract][Full Text] [Related]
39. [INHIBITORY EZH2 NOWĄ OPCJĄ TERAPEUTYCZNĄ W LECZENIU NAWROTOWEGO LUB OPORNEGO CHŁONIAKA GRUDKOWEGO EZH2 INHIBITORS AS A NEW THERAPEUTIC OPTION FOR THE TREATMENT OF RELAPSED OR RECURRENT FOLLICULAR LYMPHOMA].
Kwiatek M; Pruchniewski Ł; Kwiatek J; Kaźmierczak M; Lewandowski K
Wiad Lek; 2018; 71(5):1095-1098. PubMed ID: 30176648
[TBL] [Abstract][Full Text] [Related]
40. Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy.
Morera L; Lübbert M; Jung M
Clin Epigenetics; 2016; 8():57. PubMed ID: 27222667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]